**3. Conclusion**

This chapter has discussed the various aspects of PPM and the use of molecular and genetic profiling of tumours through omics technology for early diagnosis, formation of patient specific databases through next generation sequencing and tailored immunotherapy. Despite the advances in development technologies very few studies have been conducted in relation to OC and the research in this arena is in its budding stage. Future clinical trials on OC treatment should focus on translating the OMICs technology from bench to bedside with the use of biomarkers and CDx technologies. Tailored treatment therapies should be planned according to patients molecular and genetic profiling with consideration of individual factors. Pharma developers should create an effective medicine combining the traditional clinical data with a patient's biological profile, which includes a variety of omics-based statistics. The databases can be used to gather knowledge about disease and aid in its development more precise, safer, and better-targeted medicines for a variety of diseases in patient population.
